PDCD1 and head and neck squamous cell carcinoma: Unfortunately, overall response rates to PD-1 inhibitors in unselected patients with HNSCC remain low at approximately 10–20% (9–12), although patients who do respond can have long-lasting, durable remissions, as has been the case with other solid tumor patients who respond to PD-1 blockade (13).